Dorzagliatin Tablets | China Drugs List

Public reference information, not medical advice, a prescription or an offer to supply a medicine. Confirm current approval, availability and suitability with licensed professionals.

Brand
HuaTangNing
Company
Hua Medicine (Shanghai)
Medicine type
Chemical medicine
Therapeutic area
Endocrinology & metabolism
Indications recorded in the public source
To improve glycemic control in adults with type 2 diabetes: (1) as monotherapy alongside diet and exercise; (2) in combination with metformin hydrochloride alongside diet and exercise when metformin hydrochloride alone does not provide adequate glycemic control. Limitations of use: not indicated for type 1 diabetes, diabetic ketoacidosis or hyperosmolar hyperglycemic state.
Indication source and scope
Source date(s): 2025. Indications transcribed from the public NHSA manufacturer submission; this is not verification of the complete current label. Additional indications may be supported by newer announcements or submissions rather than the older full label; see the indication sources.
Prescribing-information limitations
Indications checked against an official public submission. The full original prescribing information is still unavailable.
China availability status
Historical Chinese approval verified; current continuous market availability has not been checked for every product.
Overseas status
Market-by-market verification pending.
Insurance classification
Included in national insurance (Category B)
Insurance edition
2025 edition; effective 1 January 2026
Insurance restrictions
Limited to type 2 diabetes.
Insurance period
2026-01-01 to 2027-12-31
Insurance verification notes
Matched by exact or normalized ingredient/formulation name. Reimbursement still depends on the dosage form and listed payment restrictions.

Sources

Open the interactive record, public price references and discussions